tiprankstipranks
Bebtelovimab losing EUA has ‘limited impact’ on Piper model for AbCellera
The Fly

Bebtelovimab losing EUA has ‘limited impact’ on Piper model for AbCellera

After the FDA removed its Emergency Use Authorization, or EUA, for COVID antibody bebtelovimab citing a lack of neutralizing activity on subvariants BQ.1 and BQ.1.1, Piper Sandler analyst Do Kim lowered his Q4 beb-mab royalty estimate and removed future sales, but said this has "limited impact" on his model for AbCellera (ABCL). The analyst, who noted that AbCellera previously confirmed a new antibody candidate has been identified under the collaboration with Eli Lilly (LLY), maintains a $21 price target and Overweight rating on AbCellera shares.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ABCL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles